Polymorphism in the Bordetella pertussisVirulence Factors P.69/Pertactin and Pertussis Toxin in The Netherlands: Temporal Trends and Evidence for Vaccine-Driven Evolution

ABSTRACT The Bordetella pertussis proteins P.69 (also designated pertactin) and pertussis toxin are important virulence factors and have been shown to confer protective immunity in animals and humans. Both proteins are used in the new generation of acellular pertussis vaccines (ACVs), and it is therefore important to study the degree of antigenic variation in these proteins. Sequence analysis of the genes for P.69 and the pertussis toxin S1 subunit, using strains collected from Dutch patients in the period 1949 to 1996, revealed three P.69 and three S1 variants which show differences in amino acid sequence. Polymorphism in P.69 was confined to a region comprised of repeats and located proximal to the RGD motif involved in adherence to host tissues. Variation in S1 was observed in two regions previously identified as T-cell epitopes. P.69 and S1 variants, identical to those included in the Dutch whole-cell pertussis vaccine (WCV), were found in 100% of the strains from the 1950s, the period when the WCV was introduced in The Netherlands. However, nonvaccine types of P.69 and S1 gradually replaced the vaccine types in later years and were found in ∼90% strains from 1990 to 1996. These results suggest that vaccination has selected for strains which are antigenically distinct from vaccine strains. Analysis of strains from vaccinated and nonvaccinated individuals indicated that the WCV protects better against strains with the vaccine type P.69 than against strains with non-vaccine types (P = 0.024). ACVs contain P.69 and S1 types which are found in only 10% of recent Dutch B. pertussis isolates, implying that they do not have an optimal composition. Our findings cast a new light on the reemergence of pertussis in highly vaccinated populations and may have major implications for the long-term efficacy of both WCVs and ACVs.

[1]  R. Andrews,et al.  Pertussis notifications in Australia, 1991 to 1997. , 1997, Communicable diseases intelligence.

[2]  F. Mooi,et al.  Pertussis in The Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. , 1997, Emerging infectious diseases.

[3]  F. Mooi,et al.  Dynamics of the population structure of Bordetella pertussis as measured by IS1002-associated RFLP: comparison of pre- and post-vaccination strains and global distribution. , 1996, Microbiology.

[4]  J. Cherry,et al.  Historical review of pertussis and the classical vaccine. , 1996, The Journal of infectious diseases.

[5]  K. Edwards,et al.  Prevalence and incidence of adult pertussis in an urban population. , 1996, JAMA.

[6]  P. Emsley,et al.  Structure of Bordetella pertussis virulence factor P.69 pertactin , 1996, Nature.

[7]  D. Kasper,et al.  Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  D Greco,et al.  A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. , 1996, The New England journal of medicine.

[9]  M. Gahr,et al.  Efficacy of acellular pertussis vaccine in early childhood after household exposure. , 1996, JAMA.

[10]  F. Mooi,et al.  From whole cell to acellular pertussis vaccines , 1996 .

[11]  W. Blackwelder,et al.  A placebo-controlled trial of a pertussis-toxoid vaccine. , 1995, The New England journal of medicine.

[12]  G. De Serres,et al.  Pertussis in Quebec: ongoing epidemic since the late 1980s. , 1995, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[13]  I. Charles,et al.  Expression of the Bordetella pertussis P.69 pertactin adhesin in Escherichia coli: fate of the carboxy-terminal domain. , 1994, Microbiology.

[14]  J. W. Bass,et al.  Return of epidemic pertussis in the United States. , 1994, The Pediatric infectious disease journal.

[15]  N. Guiso,et al.  Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species , 1993, Infection and immunity.

[16]  B. Robertson,et al.  Genetic variation in pathogenic bacteria. , 1992, Trends in genetics : TIG.

[17]  I. Charles,et al.  Cloning, nucleotide sequence and heterologous expression of the protective outer-membrane protein P.68 pertactin from Bordetella bronchiseptica. , 1992, Journal of general microbiology.

[18]  M. Brennan,et al.  Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin , 1992, Infection and immunity.

[19]  I. Charles,et al.  Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis , 1991, European journal of immunology.

[20]  P. Novotný,et al.  Identification of a 68-kilodalton outer membrane protein as the major protective antigen of Bordetella bronchiseptica by using specific-pathogen-free piglets , 1990, Infection and immunity.

[21]  M. Klein,et al.  A unique sequence of the Bordetella pertussis toxin operon. , 1989, Nucleic acids research.

[22]  I. Charles,et al.  Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Levin Frequency-dependent selection in bacterial populations. , 1988, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[24]  R. Rappuoli,et al.  Evolutionary relationships in the genus Bordetella , 1987, Molecular microbiology.

[25]  R. Rappuoli,et al.  Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[26]  C. Locht,et al.  Pertussis toxin gene: nucleotide sequence and genetic organization. , 1986, Science.

[27]  D. N. Sage,et al.  A SIMPLIFIED LIQUID CULTURE MEDIUM FOR THE GROWTH OF HEMOPHILUS PERTUSSIS , 1949, Journal of bacteriology.

[28]  M. Pizza,et al.  Acellular pertussis vaccine composed of genetically inactivated pertussis toxin. , 1995, Physiological chemistry and physics and medical NMR.

[29]  I. Charles,et al.  Recombinant P.69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection. , 1992, Vaccine.

[30]  A. Wardlaw,et al.  Pathogenesis and immunity in pertussis , 1988 .